Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 400 versus ULTRAVIST 300 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 400 versus ULTRAVIST 300 IN PLASTIC CONTAINER.
CONRAY 400 vs ULTRAVIST 300 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing radiographic contrast in imaging procedures.
Iopromide is a nonionic, low-osmolality iodinated contrast medium that attenuates X-rays due to its iodine content (300 mg iodine/mL). It provides radiographic contrast in vascular and parenchymal imaging by increasing the density of blood vessels and tissues, thereby enhancing the visibility of structures and lesions.
0.5-1.0 mL/kg (up to 150 mL total) intravenously, maximum 150 mL per procedure.
Intravenous administration of 1-2 mL/kg (300 mg iodine/mL) for contrast-enhanced CT; typical adult dose 100-150 mL (30-45 g iodine) given as bolus or rapid infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged significantly.
Terminal half-life: 2 hours in patients with normal renal function; prolonged up to 30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Renal: 90% unchanged via glomerular filtration within 24 hours; biliary: <1%; fecal: <2%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent